Tanezumab

Produc Name : Tanezumab

CAS : 880266-57-9

Molecular Formuls : C₆₄₆₄H₉₉₄₂N₁₇₀₆O₂₀₂₆S₄₆ 

Molecular Weight : 145.4 kDa

Product Description :
Tanezumab (INN, codenamed RN624) is a monoclonal antibody against nerve growth factor. It was developed by Pfizer as a treatment for pain.
In 2009 there was a Phase III trial for knee pain due to osteoarthritis. Another phase III trial for hip pain in OA was halted in June 2010 when some patients needed hip replacement.
Tanezumab is undergoing Phase II clinical trials for the treatment of various pain entities, including chronic low back pain, bone cancer pain, and interstitial cystitis.